![ART-hero-image-1920 ART-hero-image-1920](https://cellandgene.expert/hubfs/Podcast/ART-hero-image-1920.jpg)
![EU_Post-Marketing_Requirements_for_Cell_and_Gene_Therapy_Studies_Title_Card_d01](https://cellandgene.expert/hs-fs/hubfs/EU_Post-Marketing_Requirements_for_Cell_and_Gene_Therapy_Studies_Title_Card_d01.jpg?width=344&name=EU_Post-Marketing_Requirements_for_Cell_and_Gene_Therapy_Studies_Title_Card_d01.jpg)
EU Post Marketing Requirements for Cell and Gene Therapy Studies
Post-marketing requirements within the European submission process offer conditional approval more flexible than FDA. Rachel Smith, Portfolio Director for Veristat, discusses the three types of post-marketing requirements that can be requested by the EMA and draws upon the recently approved therapies – Tecartus, Zolgensma and Libmeldy, Skysona and Abecma– for real-world context.